Research programme: farnesyltransferase/geranylgeranyltransferase inhibitors - MerckAlternative Names: Farnesyltransferase/geranylgeranyltransferase inhibitors research programme - Merck
Latest Information Update: 12 Feb 2008
At a glance
- Originator Merck & Co
- Mechanism of Action Farnesyltranstransferase inhibitors; Geranylgeranyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 21 Apr 2001 Preclinical development for Cancer in USA (Unknown route)